version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Inflammation is an important driver of atherosclerosis, the underlying pathology of
cardiovascular diseases. Therefore, therapeutic targeting of inflammatory pathways is …

Background Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin–kexin
type 9. Previous studies suggest that inclisiran might provide sustained reductions in low …

Background Patients who have had an acute coronary syndrome are at high risk for
recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a …

Aims The neutrophil–lymphocyte ratio (NLR) is a readily available inflammatory biomarker
that may associate with atherosclerosis and predict cardiovascular (CV) events. The aims of …

Despite intensive preventive cardiovascular disease (CVD) efforts, substantial residual CVD
risk remains even for individuals receiving all guideline-recommended interventions. Niacin …

Background: REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl—
Intervention Trial) reported a 25% relative risk reduction in major adverse cardiovascular …

Background Lipoprotein (a) concentration is associated with cardiovascular events.
Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein (a) …

Background Experimental and clinical data suggest that reducing inflammation without
affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory …

Rationale: Coronary artery disease (CAD) is a complex phenotype driven by genetic and
environmental factors. Ninety-seven genetic risk loci have been identified to date, but the …